本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
SOUTHAMPTON, Pa., July 01, 2022 (GLOBE NEWSWIRE) -- Environmental Tectonics Corporation (OTC Pink: ETCC) (“ETC” or the “Company”) today announces that the Annual Meeting of Shareholders (“Annual Meeting”) will be held virtually via Zoom on Thursday, August 4, 2022 at 10:00 a.m. for the following purposes: To elect five (5) Directors to serve on the Board of Directors until ETC’s 2023 Annual Meeting of Shareholders and until their successors are elected. To ratify the appointment of RSM US LLP as the independent registered public accounting firm for ETC for the fiscal year ending February 24, 2023. To transact such other business as may properly come before the meeting and any adjournment of the meeting. ETC will be convening the meeting from our Corporate Headquarters via Zoom. If you would like to have the Zoom link emailed for access to the meeting, please email Andrea Morton at amorton@etcusa.com. Links will be emailed within twenty-four (24) hours of the meeting time. The Board of Directors has fixed the close of business on June 23, 2022 as the Record Date for the determination of shareholders entitled to notice of and to vote at the Annual Meeting. Materials for the Annual Meeting were made available on or about June 30, 2022 to registered shareholders as of the Record Date. Such materials are also available within the Investors section of ETC’s website at https://www.etcusa.com/investors/ shareholder-information/annual-meetingshareholders-materials/. You can vote your shares by emailing your position on each of the above items to voting@etcusa.com. If you are unable to attend the Annual Meeting, it is still important that your shares be represented. Please vote your shares promptly. ______________ About ETC: ETC designs, manufactures, and sells software driven products and services used to recreate and monitor the physiological effects of motion on humans, and equipment to control, modify, simulate and measure environmental conditions. Our products include aircrew training systems (aeromedical, tactical combat, and general), disaster management systems, sterilizers (steam and gas), environmental testing and simulation systems, and other products that involve similar manufacturing techniques and engineering technologies. ETC’s unique ability to offer complete systems, designed and produced to high technical standards, sets it apart from its competition. ETC is headquartered in Southampton, PA. For more information about ETC, visit http://www.etcusa.com/. Forward-looking Statements This news release contains forward-looking statements, which are based on management’s expectations and are subject to uncertainties and changes in circumstances. Words and expressions reflecting something other than historical fact are intended to identify forward-looking statements, and these statements may include words such as “may”, “will”, “should”, “expect”, “plan”, “anticipate”, “believe”, “estimate”, “future”, “predict”, “potential”, “intend”, or “continue”, and similar expressions. We base our forward-looking statements on our current expectations and projections about future events or future financial performance. Our forward-looking statements are subject to known and unknown risks, uncertainties and assumptions about ETC and its subsidiaries that may cause actual results to be materially different from any future results implied by these forward-looking statements. We caution you not to place undue reliance on these forward-looking statements. Contact: Joseph F. Verbitski, Jr., Chief Financial Officer Phone: (215) 355-9100 x1531 E-mail: jverbitski@etcusa.com
June 30, 2022 Solution adds proteomic analysis of blood-based biomarkers to Philips Lung Cancer Orchestrator to better assess the risk of lung nodule malignancy, enhancing decision-making for diagnosis and treatment Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced it has teamed up with Biodesix, Inc. (Colorado, U.S.) (Nasdaq: BDSX), a leading data-driven diagnostic solutions company, to incorporate the results of Biodesix’s Nodify Lung® blood-based lung nodule risk assessment testing into Philips Lung Cancer Orchestrator lung cancer patient management system. The incorporation of proteomics data – along with the radiologic and patient history data currently used to determine treatment decisions – can help create diagnostic efficiency for cancer care centers in the management of a growing number of lung nodule cases, via the contextual launch of Biodesix Nodify Lung application within Lung Cancer Orchestrator. Philips Lung Cancer Orchestrator solution is designed to enable health systems to operationalize lung cancer screening and lung nodule management programs at scale. Lung cancer remains the leading cause of cancer deaths worldwide [1], with current 5-year survival rates after diagnosis typically less than 20% [2]. If detected and treated early, however, research shows 10-year survival rates could increase to more than 90% [3]. Thanks to the adoption of low-dose CT (computer tomography) screening and better management of incidental lung nodule findings, early-stage diagnosis and treatment is now possible, but has resulted in rapidly increasing caseloads. For example, recent changes in U.S. guidelines have nearly doubled the number of people now eligible for lung cancer screening [4]. “By incorporating Biodesix’s Nodify Lung testing, we take another step in leveraging integrated diagnostics from imaging, genomics, and now proteomic results from a simple blood draw to address key moments in the lung cancer patient journey, support care team decision-making, and help health systems learn from their practice patterns in a dashboard view,” said Louis Culot, General Manager Oncology Informatics and Genomics at Philips. “We expect the inclusion of Biodesix’s ground-breaking technology in Philips Lung Cancer Orchestrator to help drive more confident decisions for the care team, and ultimately benefit patients.” As a next-step after radiologic lung nodule assessment, minimally-invasive biopsy procedures such as endobronchial biopsy (accessing a nodule via the patient’s airways), are already helping early-stage diagnosis. With 62% of biopsies conducted on benign nodules [5], by detecting the presence of blood-based biomarkers combined with clinical and radiomic factors, Biodesix’s Nodify Lung blood-based proteomic tests help clinicians to reclassify the risk of malignancy to better target resources to those who need them. If a nodule is malignant, the delay in surgical care for cancer patients by four weeks increases the mortality by 6-8% [6]. “We are delighted that our tests are being incorporated into Philips’ vision for end-to-end cancer care management using a multi-diagnostic approach,” said Scott Hutton, Chief Executive Officer at Biodesix. “By integrating our Nodify® tests in Philips Lung Cancer Orchestrator we hope to make these tests more accessible to physicians and patients and more easily utilized by care teams with the ultimate goal of improving patient care and outcomes.” Philips Lung Cancer Orchestrator is an integrated patient management system for CT lung cancer screening programs and incidental lung nodule findings that keeps track of patients, appointments, diagnostic images, test results, and clinical decisions for every step of a lung cancer patient’s screening and treatment journey. Fitting seamlessly into conventional screening and diagnostic workflows, it coordinates the end-to-end patient journey to create a fully traceable, fully documented timeline of scheduled actions, and aggregates data on tumor staging, radiology, pathology, and biomarker analyses for informed decision-making. The ability to order and receive the results expedites Biodesix’s proteomic testing directly to and from the Lung Cancer Orchestrator at the same time it adds new insights on nodule risk of malignancy to further support the decision-making process. Lung Cancer Orchestrator is part of Philips’ expanding portfolio of integrated cancer care solutions that seamlessly connect data, technology, operations, and clinical workflows to enable pivotal decision-making. Visit Philips Oncology to learn how Philips combines smart diagnostic and imaging technologies with connected workflows that integrate patient data from disparate systems, to provide solutions that put expert information at clinicians’ fingertips to help expand the quality and reach of personalized cancer care. [1] International Agency for Research on Cancer, World Health Organization. Press Release N° 263. Latest global cancer data: Cancer burden rises to 18.1 million new cases and 9.6 million cancer deaths in 2018. 12 September 2018 [2]https://www.medicinenet.com/what_is_the_most_survivable_cancer/article.htm [3] International Early Lung Cancer Action Program Investigators. Survival of patients with stage 1 lung cancer detected on CT screening. N Engl J Med. 2006;355:1763- 1771 DOI: 10.1056/NEJMoa060476. [4] Lane E, et al. Nearly twice as many people are now eligible for lung cancer screenings—here is what you need to know. Advisory Board publication. 2021.Washington, DC. https://www.advisory.com/sponsored/lung-cancer [5] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4665735/ [6] Mortality due to cancer treatment delay: systematic review and meta-analysis. BMJ 2020;371:m4087 http://dx.doi.org/10.1136/bmj.m4087 For further information, please contact: Kathy O’Reilly Philips Global Press Office Tel.: +1 978-221-8919 E-mail: kathy.oreilly@philips.com Twitter: @kathyoreilly About Royal Philips Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2021 sales of EUR 17.2 billion and employs approximately 78,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter. About Biodesix Biodesix is a leading data-driven diagnostic solutions company with a focus in lung disease. The Company develops diagnostic tests addressing important clinical questions by combining multi-omics through the power of artificial intelligence. Biodesix is the first company to offer eight non-invasive tests for patients with lung diseases. The blood based Nodify Lung® nodule risk assessment testing strategy, consisting of the Nodify XL2® and the Nodify CDT® tests, evaluates the risk of malignancy in incidental pulmonary nodules, enabling physicians to better triage patients to the most appropriate course of action. The blood based IQLung™ strategy for lung cancer patients integrates the GeneStrat® ddPCR™ test, the GeneStrat NGS™ test and the VeriStrat® test to support treatment decisions across all stages of lung cancer with results in an unprecedented 36-72 hours, expediting time to treatment. Biodesix also leverages the proprietary and advanced Diagnostic Cortex® AI (Artificial Intelligence) platform, to collaborate with many of the world’s leading biotechnology and pharmaceutical companies to solve complex diagnostic challenges in lung disease. Biodesix launched the SARS-CoV-2 ddPCR™ test, the Platelia SARS-CoV-2 Total Ab, and the cPass™ SARS-CoV-2 Neutralization Antibody test (cPass™ Neutralization Test Kit, GenScript, Inc,) in response to the global pandemic and virus that impacts the lung and causes COVID-19. For more information about Biodesix, visit biodesix.com.
Sinch Ranked Tier One by ROCCO Sinch ranked Tier 1 in ROCCO's latest reports for SMS Firewall and A2P SMS Vendors Stockholm, Sweden – 23 June 2022 – Sinch AB (publ), a global leader in cloud communications and mobile customer engagement, today announced that it has been awarded the highest ‘Tier One’ ranking in recent reports from Roaming Consulting Company (ROCCO) for its Application-to-Person (A2P) SMS Monetization suite and A2P SMS Firewall product for MNOs, and A2P SMS products for enterprises, which are key elements of the SMS product suite. A2P Monetization provides MNOs the ability to simultaneously generate new revenue, boost security of the network, enhance subscriber privacy and increase customer satisfaction. It allows operators to close off their network to un-authorised routed SMS traffic using tools like the SMS Firewall and to direct these messages to legal and monetized routes “As SMS-related fraud has become more pervasive, it is crucial for operators and their enterprise customers to find the right vendor they can trust that can monetize SMS while preventing subscribers from suffering fraud,” said Helene Henriksson, managing director, Operator Messaging, Sinch. “ROCCO’s rankings of our A2P SMS Monetization suite and SMS Firewall product show Sinch’s A2P messaging services are therefore trusted by operators and are about far more than simple connectivity and monetization. Sinch also offers MNOs even greater value by providing their enterprise customers with analysis, statistics and performance trends which means our products are providing support and optimization for any enterprise.” With more than 600 direct carrier connections, Sinch’s A2P SMS offering enables businesses in any industry to expand their reach, engage with customers globally and enhance customer experiences, all while enjoying highest delivery rates, lowest latency and built-in global compliance. MNOs and enterprises were surveyed by ROCCO directly and they were highly complementary of Sinch, with several stating in the ROCCO report that Sinch is a very proactive partner, willing to support businesses and having excellent industry insight, whilst also growing revenues, safeguarding their subscribers, and protecting their enterprise customers and brands. Click here for more information on Sinch’s products rated by ROCCO and to purchase the reports. For further information, please contact Marcel Kay Global Public Relations Director Mobile: +44 7572 780077 E-mail: marcel.kay@sinch.com About Sinch Sinch’s leading cloud communications platform lets businesses reach everyone on the planet, in seconds or less, through mobile messaging, email, voice and video. More than 150,000 businesses, including many of the world’s largest companies and mobile operators, use Sinch’s advanced technology platform to engage with their customers. Sinch has been profitable and fast-growing since its foundation in 2008. It is headquartered in Stockholm, Sweden, and has local presence in more than 50 countries. Shares are traded at NASDAQ Stockholm: XSTO:SINCH. Visit us at sinch.com. About ROCCO ROCCO was founded in 2012 and from its conception has been a catalyst for innovation with Research, Strategy and Education for the telecoms industry. Creating reports on Roaming, Messaging and Fraud and Security, ROCCO delivers on-demand training and strategic consulting which together provide a rich foundation on which to build strategic excellence. With ROCCO’s insights, Mobile Operators, their vendors and Enterprises globally can face connectivity challenges more robustly. Attachment Sinch Ranked Tier One by ROCCO
SOUTHAMPTON, Pa., June 20, 2022 (GLOBE NEWSWIRE) -- Environmental Tectonics Corporation’s (OTC Pink: ETCC) (“ETC” or the “Company”) today announced that on June 15, 2022, the Company closed a transaction to sell and lease back our property located in Southampton, Pennsylvania. This property sold consists of our corporate headquarters, main production plant, and the NASTAR Center. Under the terms of the sale agreement, the land, buildings, and improvements, with a net book value of $2,250,000, were sold for pre-tax net proceeds of $4,700,000, resulting in a net gain on the sale of approximately $2,400,000. Existing training equipment in the NASTAR Center affixed to the building was not included in the sale. In connection with the sale, the Company entered into an Agreement of Lease ("Lease") with VV100 LLC as to an undivided 82.53% interest and The Irrevocable Agreement of Trust of Jerry D. Kratz for the Benefit of Descendants dated December 19, 2011, as to an undivided 17.47% interest, as tenants in common (collectively, "Lessor") for Lessor to lease back to the Company all the property sold. The property has been leased back for an initial term of seven (7) years (“Initial Term”), and the Lease includes specified renewal options for up to seven (7) additional years (“Renewal Term”). Net rent expense for the first year of the Lease is $420,000 annually, and increases 2.5% for each additional year of the Initial Term. At the outset of the Renewal Term, rent will reset to fair market value and will increase 3.0% for each additional year of the Renewal Term. The property sold had depreciation expense of approximately $165,000 annually. Net proceeds from the sale are being used initially to reduce outstanding borrowings under our credit facility with PNC Bank. About ETC: ETC designs, manufactures, and sells software driven products and services used to recreate and monitor the physiological effects of motion on humans, and equipment to control, modify, simulate and measure environmental conditions. Our products include aircrew training systems (aeromedical, tactical combat, and general), disaster management systems, sterilizers (steam and gas), environmental testing and simulation systems, and other products that involve similar manufacturing techniques and engineering technologies. ETC’s unique ability to offer complete systems, designed and produced to high technical standards, sets it apart from its competition. ETC is headquartered in Southampton, PA. For more information about ETC, visit http://www.etcusa.com/. Forward-looking Statements This news release contains forward-looking statements, which are based on management’s expectations and are subject to uncertainties and changes in circumstances. Words and expressions reflecting something other than historical fact are intended to identify forward-looking statements, and these statements may include words such as “may”, “will”, “should”, “expect”, “plan”, “anticipate”, “believe”, “estimate”, “future”, “predict”, “potential”, “intend”, or “continue”, and similar expressions. We base our forward-looking statements on our current expectations and projections about future events or future financial performance. Our forward-looking statements are subject to known and unknown risks, uncertainties and assumptions about ETC and its subsidiaries that may cause actual results to be materially different from any future results implied by these forward-looking statements. We caution you not to place undue reliance on these forward-looking statements. Contact: Joseph F. Verbitski, Jr., Chief Financial Officer Phone: (215) 355-9100 x1531 E-mail: jverbitski@etcusa.com
BEIJING, June 15, 2022 /PRNewswire/ -- Waterdrop Inc. ("Waterdrop", the "Company" or "we") (NYSE: WDH), a leading technology platform dedicated to insurance and healthcare service with a positive social impact, today announced its unaudited financial results for the first quarter ended March 31, 2022. Financial and Operational Highlights for the First Quarter of 2022 Recovery to positive business growth: For the first quarter of 2022, the first-year premiums ("FYP") generated through our Waterdrop Insurance Marketplace amounted to RMB1,866.1 million (US$294.4 million), and our net operating revenue was RMB648.7 million (US$102.3 million) which represented an increase of 7.4% quarter over quarter, resuming positive growth after our business strategy has been adjusted from pursuing fast growth to enhancing quality development and profitability. Effective cost control and consistent profitability improvement: For the first quarter of 2022, our sales and marketing expenses decreased by 75.6%, and total operating costs and expenses decreased by 60.4% year over year, respectively, resulting in a US GAAP net profit of RMB105.0 million (US$16.6 million) for the first time following the non-GAAP profit in the fourth quarter of 2021. Our non-GAAP net profit was RMB127.3 million (US$20.1 million) for the first quarter of 2022, a significant increase quarter over quarter. These results have showcased our effective cost control and consistent commitment to achieving profitability. Steady growth in the number of insurance customers: The number of cumulative insurance customers reached 111.1 million and cumulative paying insurance customers reached 28.8 million as of March 31, 2022. Positive cash flow: As of March 31, 2022, our cash and cash equivalents and short-term investment balance increased by RMB137.1 million from the end of 2021 to RMB2,924.2 million (US$461.3 million), as we continued to generate positive operating cash flow, partially offset by the investing and financing cash outflow. Further expanded product offerings: As of March 31, 2022, we offered 408 insurance products on our platform, as compared with 364 as of December 31, 2021. Over 90% of the FYP generated through our Waterdrop Insurance Marketplace was contributed by our exclusive customized insurance products. In the first quarter of 2022, the FYP of critical illness insurance increased by 39.9% quarter over quarter, and accounted for 27.6% of overall FYP, up by 8.2 percentage points as compared with the fourth quarter of 2021. As of March 31, 2022, over 403 million people cumulatively donated an aggregate of approximately RMB50.9 billion to nearly 2.5 million patients through our Waterdrop Medical Crowdfunding. Mr. Peng Shen, Founder, Chairman, and Chief Executive Officer of Waterdrop, commented, "2022 marks the sixth anniversary of Waterdrop, and we are embracing a new beginning. For the first quarter of 2022, I am pleased to report we achieved a US GAAP net profit for the first time in our operating history after turning profitable on a non-GAAP basis in the prior quarter. We managed to further reduce sales and marketing expenses and operating costs. Our operating performance and business trends over the past two quarters also increased our confidence in being able to keep the momentum and achieve the overall profitability goal we set for the full year. For our insurance business, the first quarter of 2022 was the second full quarter after upgrading our business model, and we have already significantly improved our operational efficiencies. We systematically optimized the operating model of 'multi-platform, multi-supply and multi-service mode'. We leveraged innovative operational scenarios to effectively increase engagement with users, and further increased the repurchase rate and renewal rate to over 70% and 90%, respectively. We also added new medical insurance products to our portfolio such as the chronic disease and the kidney disease-specific versions, and launched multiple critical illness protection plans that cater to the needs of diverse customer groups with different price sensitivities. Meanwhile, we continued to evolve our AI-empowered business and increased our efforts in exporting our AI capabilities to our insurance partners. In terms of healthcare business exploration, we made further progress in solidifying our market position in patient recruitment for clinical trials. We helped with the enrollment of over 50 new clinical trial programs by partnering with leading domestic and international pharmaceutical companies. Over 500 patients have been successfully registered for clinical trial programs on our platform in the first quarter, representing a solid growth compared with the previous quarter. Leveraging our large patient pool and capability in precisely and efficiently matching patients with suitable programs on our AI-powered platform, we have effectively addressed the pain points of patient recruitment services and are fully committed to becoming one of the best third-party patient recruitment platforms. As a company with positive social impact and strong sense of ESG responsibilities, we became a participant of the United Nations Global Compact (UNGC), joining hands with more than 16,000 companies in 161 countries around the world to shape a sustainable future together. We remain committed to our mission of 'leveraging internet technologies to make insurance protection more inclusive and accessible to all, and bring insurance and healthcare service to billions'. We also proactively leveraged our competitive strengths and digital service capabilities to promote, implement and achieve our sustainable development goals." Financial Results for the First Quarter of 2022 Operating revenue, net Net operating revenue for the first quarter of 2022 decreased by 26.6% year over year to RMB648.7 million (US$102.3 million) from RMB883.4 million for the same period of 2021, which was primarily due to the decrease in insurance-related income. The net operating revenue increased by 7.4% compared with the fourth quarter of 2021, mainly driven by the increase in insurance-related income. Insurance-related income includes insurance brokerage income and technical service income. Insurance brokerage income represents brokerage commissions earned from insurance companies. Technical service income is derived from providing technical services to insurance companies, insurance brokerage, and agency companies, which include customer relationship maintenance, customer complaint management, claim review, user referral services, among other things. Our insurance-related income amounted to RMB628.2 million (US$99.1 million) in the first quarter of 2022, representing a decrease of 23.9% year over year from RMB825.4 million for the first quarter of 2021, which was mainly due to the decrease in insurance brokerage income. Net operating revenue from management fee income was nil for the first quarter of 2022, compared to RMB2.7 million for the same quarter of 2021, which was mainly due to the cessation of the mutual aid business at the end of March 2021. Following this adjustment, the corresponding management fee income from the mutual aid business is no longer a revenue stream for the Company from the second quarter of 2021 and onwards. Excluding such management fee income, the adjusted net operating revenue(1) for the first quarter of 2022 decreased by 26.3% compared with the same period of 2021. Note: (1) See the sections entitled "Non-GAAP Financial Measures" for more information. Operating costs and expenses Operating costs and expenses decreased by 60.4% year over year and 21.5% quarter over quarter to RMB532.0 million (US$83.9 million) for the first quarter of 2022, due to the effective cost control measures taken since the third quarter of 2021. Operating costs decreased by 48.5% year over year to RMB154.9 million (US$24.4 million) for the first quarter of 2022, compared with RMB300.6 million for the first quarter of 2021, which was primarily driven by (i) RMB38.6 million decrease in professional and outsourced customer service fees; (ii) RMB5.2 million decrease in payout investigation cost due to the cessation of mutual aid business, (iii) a decrease of RMB35.3 million in personnel cost for our expanded consultants and insurance agents team and (iv) a decrease of RMB76.8 million in relation to the cessation of the Waterdrop Mutual Aid business. On a quarter-over-quarter basis, operating costs decreased by 21.4% as compared to the fourth quarter of 2021, primarily due to a decrease of RMB44.9 million in personnel costs. Sales and marketing expenses decreased materially by 75.6% year over year to RMB204.3 million (US$32.2 million) for the first quarter of 2022, compared with RMB837.2 million for the first quarter of 2021. The decrease was primarily due to (i) RMB619.8 million decrease in marketing expenses to third-party traffic channels and (ii) RMB17.9 million decrease in outsourced sales and marketing service fees to third parties, offset by an increase of RMB14.4 million in payroll and related expenses for the employees involved in sales and marketing functions. On a quarter-over-quarter basis, sales and marketing expenses decreased by 15.2% from RMB241.0 million for the fourth quarter of 2021. This was mainly due to the decrease of RMB26.5 million in marketing expenses to third-party traffic channels, RMB5.4 million in payroll and related expenses for employees, and RMB3.3 million in outsourced sales and marketing service fees to third parties under our cost control plan and more strict budgeting for expenses. General and administrative expenses decreased by 15.9% year over year to RMB102.0 million (US$16.1 million) for the first quarter of 2022, compared with RMB121.3 million for the first quarter of 2021. The year-over-year variance was a net impact of the decrease of RMB45.1 million in share-based compensation expenses offset by (i) RMB7.2 million increase in D&O insurance premiums, (ii) RMB4.7 million increase in professional service fees, and (iii) RMB11.5 million increase in allowance for doubtful accounts. On a quarter-over-quarter basis, general and administrative expenses decreased by 31.4% from RMB148.7 million for the fourth quarter of 2021, which was mainly due to the combined impact of a decrease of RMB39.0 million in impairment loss and RMB15.9 million in personnel cost and share-based compensation expenses. Research and development expenses decreased by 16.6% year over year to RMB70.8 million (US$11.2 million) for the first quarter of 2022, compared with RMB84.9 million for the same period of 2021. The decrease was primarily due to RMB13.8 million decreases in research and development personnel costs and share-based compensation expenses. On a quarter-over-quarter basis, research and development expenses decreased by 22.1% compared to the fourth quarter of 2021, mainly due to the optimization of our organizational structure. Operating profit for the first quarter of 2022 was RMB116.6 million (US$18.4 million), compared with an operating loss of RMB460.6 million for the first quarter of 2021 and a loss of RMB73.9 million for the fourth quarter of 2021. Interest income for the first quarter of 2022 was RMB14.5 million (US$2.3 million), compared with RMB13.2 million for the same period of 2021. The increase was primarily due to the increase in our bank balance and short-term investments as a result of the receipt of net proceeds from the completion of our initial public offering in May 2021 and positive operating cash flow generated from the business during the first quarter of 2022. Income tax expense for the first quarter of 2022 was RMB51.3 million (US$8.1 million), compared with an income tax benefit of RMB74.3 million for the same period of 2021. Net profit attributable to Waterdrop for the first quarter of 2022 was RMB105.0 million (US$16.6 million), compared with a net loss of RMB370.2 million for the same period of 2021, and a net loss of RMB71.2 million for the fourth quarter of 2021. Adjusted net profit attributable to Waterdrop for the first quarter of 2022 was RMB127.3 million (US$20.1 million), compared with an adjusted net loss of RMB203.1 million for the same period of 2021, and an adjusted net profit of RMB5.9 million for the fourth quarter of 2021. Cash and cash equivalents and short-term investment As of March 31, 2022, the Company had combined cash and cash equivalents and short-term investments of RMB2,924.2 million (US$461.3 million), as compared with RMB2,787.1 million as of December 31, 2021. Share Repurchase Plan Pursuant to the 12-month share repurchase program announced on September 8, 2021, since the announcement up to the end of the first quarter of 2022, we cumulatively repurchased approximately 3.1 million ADSs from the open market with cash for a total consideration of approximately US$5.1 million. Business Outlook The Company expects to achieve overall profitability on a non-GAAP basis for the year 2022 under the circumstances that we keep investing in established businesses and new initiatives. We also expect the net operating revenue growth to continue quarter over quarter in the second quarter of 2022. This forecast is based on the current market conditions and reflects the Company's preliminary view and estimates, which are all subject to changes. Exchange Rate This announcement contains translations of certain RMB amounts into U.S. dollars ("USD" or "US$") at specified rates solely for the convenience of the reader. Unless otherwise stated, all translations from RMB to USD were made at the rate of RMB6.3393 to US$1.00, the noon buying rate in effect on March 31, 2022 in the H.10 statistical release of the Federal Reserve Board. The Company makes no representation that the RMB or USD amounts referred could be converted into USD or RMB, as the case may be, at any particular rate or at all. For analytical presentation, all percentages are calculated using the numbers presented in the financial statements contained in this earnings release. Non-GAAP Financial Measures The Company uses non-GAAP financial measures, such as adjusted net operating revenue and adjusted net profit/loss, in evaluating the Company's operating results and for financial and operational decision-making purposes. Adjusted net operating revenue represents net operating revenue excluding management fee income from mutual aid business. Adjusted net profit/loss represents net profit/loss excluding share-based compensation expense, the impact of terminating the mutual aid plan, foreign currency exchange gain or losses, impairment loss, and share of results of equity method investee. Such adjustments have no impact on income tax. The non-GAAP financial measures are not presented in accordance with U.S. GAAP and may be different from non-GAAP methods of accounting and reporting used by other companies. The non-GAAP financial measures have limitations as analytical tools and when assessing the Company's operating performance, investors should not consider them in isolation, or as a substitute for net loss or other consolidated statements of comprehensive loss data prepared in accordance with U.S. GAAP. The Company encourages investors and others to review its financial information in its entirety and not rely on a single financial measure. Investors are encouraged to review the Company's historical non-GAAP financial measures to the most directly comparable GAAP measures. Adjusted net operating revenue and adjusted net profit/loss presented here may not be comparable to similarly titled measures presented by other companies. Other companies may calculate similarly titled measures differently, limiting their usefulness as comparative measures to our data. The Company encourages investors and others to review its financial information in its entirety and not rely on a single financial measure. The Company mitigates these limitations by reconciling the non-GAAP financial measures to the most comparable U.S. GAAP performance measures, all of which should be considered when evaluating the Company's performance. For more information on the non-GAAP financial measures, please see the table captioned "Reconciliation of GAAP and Non-GAAP Results" set forth at the end of this press release. Safe Harbor Statement This press release contains statements that may constitute "forward-looking" statements pursuant to the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "aims," "future," "intends," "plans," "believes," "estimates," "likely to" and similar statements. Among other things, quotations in this announcement, contain forward-looking statements. Waterdrop may also make written or oral forward-looking statements in its periodic reports to the Securities and Exchange Commission (the "SEC"), in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about Waterdrop's beliefs, plans and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: Waterdrop's mission, goals and strategies; Waterdrop's future business development, financial condition and results of operations; the expected growth of the insurance, medical crowdfunding and healthcare industry in China; Waterdrop's expectations regarding demand for and market acceptance of our products and services; Waterdrop's expectations regarding its relationships with consumers, insurance carriers and other partners; competition in the industry and relevant government policies and regulations relating to insurance, medical crowdfunding and healthcare industry. Further information regarding these and other risks is included in Waterdrop's filings with the SEC. All information provided in this press release is as of the date of this press release, and Waterdrop does not undertake any obligation to update any forward-looking statement, except as required under applicable law. Conference Call Information Waterdrop's management team will hold a conference call on June 15, 2022 at 8:00 AM U.S. Eastern Time (8:00 PM Beijing/Hong Kong Time on the same day) to discuss the financial results. Dial-in details for the earnings conference call are as follows: International: 1-412-317-6061 United States Toll Free: 1-888-317-6003 Hong Kong Toll Free: 800-963976 Hong Kong: 852-58081995 Mainland China: 4001-206115 Elite Entry Number: 8558252 Please dial in 15 minutes before the call is scheduled to begin and provide the Elite Entry Number to join the call. A telephone replay will be accessible two hours after the conclusion of the conference call through June 22, 2022 by dialing the following numbers: United States Toll Free: 1-877-344-7529 International: 1-412-317-0088 Access Code: 4166042 A live and archived webcast of the conference call will also be available at the Company's investor relations website at http://ir.waterdrop-inc.com/. About Waterdrop Inc. Waterdrop Inc. (NYSE: WDH) is a leading technology platform dedicated to insurance and healthcare service with a positive social impact. Founded in 2016, with the comprehensive coverage of Waterdrop Insurance Marketplace and Waterdrop Medical Crowdfunding, Waterdrop aims to bring insurance and healthcare service to billions through technology. For more information, please visit www.waterdrop-inc.com. For investor inquiries, please contact Waterdrop Inc.Xiaojiao CuiIR@shuidi-inc.com ChristensenIn ChinaMr. Eric YuanPhone: +86-1380-111-0739E-mail: Eyuan@christensenir.com In the USMs. Linda BergkampPhone: +1-480-614-3004Email: lbergkamp@christensenir.com WATERDROP INC. UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (All amounts in thousands, unless otherwise noted) As of December 31, 2021 March 31, 2022 RMB RMB USD Assets Current assets Cash and cash equivalents 817,719 334,275 52,731 Restricted cash 667,664 516,457 81,469 Short-term investments 1,969,362 2,589,917 408,549 Accounts receivable, net 643,843 687,696 108,481 Inventories, net - 326 51 Current contract assets 563,611 466,770 73,631 Amount due from related parties 1,049 169 27 Prepaid expense and other assets 369,794 353,471 55,760 Total current assets 5,033,042 4,949,081 780,699 Non-current assets Non-current contract assets 29,889 50,410 7,952 Property, equipment and software, net 44,762 40,920 6,455 Intangible assets, net 56,753 56,718 8,947 Long-term investments 11,812 11,802 1,862 Right of use assets, net 59,081 52,076 8,215 Deferred tax assets 11,840 - - Goodwill 3,420 3,420 539 Total non-current assets 217,557 215,346 33,970 Total assets 5,250,599 5,164,427 814,669 Liabilities and Shareholders' Equity Current liabilities Amount due to related parties 20,449 16,036 2,530 Insurance premium payables 685,028 520,212 82,061 Deferred revenue 803 1,028 162 Accrued expenses and other current liabilities 498,752 447,761 70,633 Current lease liabilities 44,113 33,245 5,244 Total current liabilities 1,249,145 1,018,282 160,630 Non-current liabilities Non-current lease liabilities 14,477 12,070 1,904 Deferred tax liabilities 13,551 52,723 8,317 Total non-current liabilities 28,028 64,793 10,221 Total liabilities 1,277,173 1,083,075 170,851 Shareholders' equity Class A ordinary shares 107 107 17 Class B ordinary shares 27 27 4 Treasury stock - (1) - Additional paid-in capital 7,329,420 7,339,100 1,157,715 Accumulated other comprehensive loss (21,492) (28,203) (4,449) Accumulated deficit (3,334,636) (3,229,678) (509,469) Total shareholders' equity 3,973,426 4,081,352 643,818 Total liabilities and shareholders' equity 5,250,599 5,164,427 814,669 WATERDROP INC. UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (All amounts in thousands, except for share and per share data, or otherwise noted) For the Three Months Ended March 31, 2021 December 31, 2021 March 31, 2022 RMB RMB RMB USD Operating revenue, net 883,367 603,888 648,688 102,328 Operating costs and expenses(i) Operating costs (300,608) (197,133) (154,880) (24,432) Sales and marketing expenses (837,153) (241,010) (204,343) (32,234) General and administrative expenses (121,287) (148,715) (101,995) (16,089) Research and development expenses (84,875) (90,967) (70,825) (11,172) Total operating costs and expenses (1,343,923) (677,825) (532,043) (83,927) Operating (loss)/profit (460,556) (73,937) 116,645 18,401 Other income Interest income 13,215 12,192 14,492 2,286 Foreign currency exchange gain/(loss) 784 (5,616) 653 103 Others, net 2,101 1,198 24,489 3,863 (Loss)/profit before income tax, and share of loss in equity method investee (444,456) (66,163) 156,279 24,653 Income tax benefit/(expense) 74,300 (5,034) (51,321) (8,096) Net (loss)/profit attributable to Waterdrop Inc. (370,156) (71,197) 104,958 16,557 Preferred shares redemption value accretion (110,287) - - - Net (loss)/profit attributable to ordinary shareholders (480,443) (71,197) 104,958 16,557 Net (loss)/profit (370,156) (71,197) 104,958 16,557 Other comprehensive (loss)/income : Foreign currency translation adjustment, net of tax (2,782) (10,465) (7,783) (1,228) Unrealized gains on available for sale investments, net of tax 1,067 154 1,072 169 Comprehensive (loss)/income (371,871) (81,508) 98,247 15,498 Weighted average number of ordinary shares used in computing net (loss)/profit per share Basic 1,191,599,014 3,935,102,446 3,938,758,720 3,938,758,720 Diluted 1,191,599,014 3,935,102,446 4,017,949,706 4,017,949,706 Net (loss)/profit per share attributable to ordinary shareholders Basic (0.40) (0.02) 0.03 0.00 Diluted (0.40) (0.02) 0.03 0.00 (i) Share-based compensation expenses are included in the operating costs and expenses as follows. For the Three Months Ended March 31, 2021 December 31, 2021 March 31, 2022 RMB RMB RMB USD Sales and marketing expenses (2,981) (1,876) (2,802) (442) General and administrative expenses (62,021) (25,880) (16,921) (2,669) Research and development expenses (6,176) (4,018) (3,284) (518) Total (71,178) (31,774) (23,007) (3,629) WATERDROP INC. RECONCILIATIONS OF GAAP AND NON-GAAP RESULTS (All amounts in thousands, unless otherwise noted) For the Three Months Ended March 31, 2021 December 31, 2021 March 31, 2022 RMB RMB RMB USD Net operating revenue 883,367 603,888 648,688 102,328 Less: Management fee income 2,745(ii) - - - Adjusted net operating revenue 880,622 603,888 648,688 102,328 For the Three Months Ended March 31, 2021 December 31, 2021 March 31, 2022 RMB RMB RMB USD Net (loss)/profit (370,156) (71,197) 104,958 16,557 Add: Share-based compensation expense 71,178 31,774 23,007 3,629 Foreign currency exchange (gain)/loss (784) 5,616 (653) (103) Impact of terminating the mutual aid plan (iii) 96,697 - - - Impairment loss - 39,717 - - Adjusted net (loss)/profit (203,065) 5,910 127,312 20,083 (ii) This represents the net management fee revenue related to the mutual aid business for the three months ended March 31, 2021 after recording the RMB19.9 million reduction of management fee revenue previously recognized for each participant to the extent of the cumulative amount earned until March 26, 2021. (iii) This represents the estimated cost of medical expenses and cost of one-year health insurance coverage. RMB19.9 million (US$3.1 million) was accounted for as a reduction of management fee revenue previously recognized for each participant to the extent of the cumulative amount earned until March 26, 2021. RMB76.8 million (US$12.1 million) was recorded as operating costs.
June 13, 2022 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA) today announced that it will repurchase up to 3.2 million shares to cover certain of its obligations arising from its long-term incentive and employee stock purchase plans. At the current share price, the shares represent an amount of up to approximately EUR 68 million. The repurchases will be executed through one or more individual forward transactions, expected to be entered into in the second and/or the third quarter of 2022, in accordance with the Market Abuse Regulation and within the limits of the authorization granted by the company’s General Meeting of Shareholders on May 10, 2022. Philips expects to take delivery of the shares in 2024. Further details will be available via this link. For further information, please contact: Ben Zwirs Philips Global Press Office Tel.: +31 6 1521 3446 E-mail: ben.zwirs@philips.com Derya Guzel Philips Investor Relations Tel.: +31 20 59 77055 E-mail: derya.guzel@philips.com About Royal Philips Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2021 sales of EUR 17.2 billion and employs approximately 79,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter. Forward-looking statements This release contains certain forward-looking statements with respect to the financial condition, results of operations and business of Philips and certain of the plans and objectives of Philips with respect to these items. Examples of forward-looking statements include statements made about the strategy, estimates of sales growth, future EBITA, future developments in Philips’ organic business and the completion of acquisitions and divestments. By their nature, these statements involve risk and uncertainty because they relate to future events and circumstances and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these statements.
A12 藝術空間
Mail
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
